David R Owens (D R Owens, David Owens)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 18

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

Diabetes technology & therapeutics

Diabetic medicine : a journal of the British Diabetic Association

Swansea University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Swansea University

United Kingdom

Professor :: Diabetes Research Group

Publications

Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial. Diabetes, obesity & metabolism (2023)
Claude Colette, Claude Colette, David R Owens
Below Which Threshold of Glycemic Variability Is There a Minimal Risk of Hypoglycemia in People with Type 2 Diabetes? Diabetes technology & therapeutics 24 (6) (2022)
Claude Colette, Claude Colette, David R Owens
Three Key Indices in Clinical Practice to Better Comprehend the Postprandial and Basal Glucose Contributions in Type 2 Diabetes. Diabetes technology & therapeutics 24 (11) (2022)
David R Owens, Louis Monnier, Antonio Ceriello, Geremia B Bolli
Insulin Centennial: Milestones influencing the development of insulin preparations since 1922. Diabetes, obesity & metabolism (2021)
Rebecca L Thomas, Wai Yee Cheung, James M Rafferty, Stephen D Luzio, Ashley Akbari, David R Owens
Characteristics of repeat non-attenders at Diabetes Eye Screening Wales, a national community-based diabetes-related retinopathy screening service, during 2003-2018. Diabetic medicine : a journal of the British Diabetic Association 38 (9) (2021)
David R Owens, Geremia B Bolli
The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. Diabetes, obesity & metabolism 22 (5) (2020)
Natalie Nanayakkara, Andrea J Curtis, Stephane Heritier, Adelle M Gadowski, Meda E Pavkov, Timothy Kenealy, David R Owens, Rebecca L Thomas, Soon H Song, Jencia Wong, Juliana Chung Ngor Chan, Andrea On Yan Luk, Giuseppe Penno, Xiantong Zou, Viswanathan Mohan, Anandakumar Amutha, Romero-Aroca Pedro, Danijela Gasevic, Dianna J Magliano, Helena J Teede, John Chalmers, Sophia Zoungas
Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia 64 (2) (2020)
David R Owens, Wolfgang Landgraf, Brian M Frier, Mei Zhang, Philip D Home, Stephen H Mandy, Geremia B Bolli
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. Diabetes, obesity & metabolism 21 (2) (2019)
Wolfgang Landgraf, David R Owens, Brian M Frier, Mei Zhang, Geremia B Bolli
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes, obesity & metabolism 22 (3) (2019)
Sharon Parsons, Stephen D Luzio, J N Harvey, Stephen C Bain, W Y Cheung, Alan Watkins, David R Owens
Effect of structured self-monitoring of blood glucose, with and without additional TeleCare support, on overall glycaemic control in non-insulin treated Type 2 diabetes: the SMBG Study, a 12-month randomized controlled trial. Diabetic medicine : a journal of the British Diabetic Association 36 (5) (2019)
Brian M Frier, Wolfgang Landgraf, Mei Zhang, Geremia B Bolli, David R Owens
Hypoglycaemia risk in the first 8 weeks of titration with insulin glargine 100 U/mL in previously insulin-naive individuals with type 2 diabetes mellitus. Diabetes, obesity & metabolism 20 (12) (2018)
David R Owens, Geremia B Bolli, Bernard Charbonnel, Thomas Haak, Wolfgang Landgraf, Francesca Porcellati, Louise Traylor, Alexandra Kautzky-Willer
Effects of age, gender, and body mass index on efficacy and hypoglycaemia outcomes across treat-to-target trials with insulin glargine 100 U/mL added to oral antidiabetes agents in type 2 diabetes. Diabetes, obesity & metabolism 19 (11) (2017)
David R Owens, Louis Monnier, Anthony H Barnett
Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy. Diabetes, obesity & metabolism 19 (10) (2017)
David R Owens, Louis Monnier, Markolf Hanefeld
A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus. Diabetes, obesity & metabolism 19 (12) (2017)

David R Owens.css-eqlu8i{font-size:small;padding-left:4px;} (D R Owens, David Owens)

Publication Activity (10 Years)

Top Topics

Top Venues

David R Owens (D R Owens, David Owens)